These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35845284)

  • 1. Real-world treatment patterns, adverse events and clinical outcomes in patients with chronic lymphocytic leukaemia treated with ibrutinib in the UK.
    Hillmen P; Xie J; Yong ASM; Waweru C; Sorof TA; Goyal RK; Davis KL
    EJHaem; 2021 May; 2(2):219-227. PubMed ID: 35845284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results from a Real-World Multicenter Analysis of 482 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Look at Racial Differences.
    Barrientos JC; Ayed AO; Cha A; Du S; Fang B; Hall R; Marks SM; Peng E; Rhodes JM; Ryan K; Winters SB; Yeung PL; Hou JZ
    Target Oncol; 2023 Sep; 18(5):727-734. PubMed ID: 37728835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study.
    Moldovianu AM; Stoia R; Vasilica M; Ursuleac I; Badelita SN; Tomescu AA; Preda OD; Bardas A; Cirstea M; Coriu D
    Medicina (Kaunas); 2023 Feb; 59(2):. PubMed ID: 36837525
    [No Abstract]   [Full Text] [Related]  

  • 4. Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia.
    Hou JZ; Ryan K; Du S; Fang B; Marks S; Page R; Peng E; Szymanski K; Winters S; Le H
    Future Oncol; 2021 Dec; 17(35):4959-4969. PubMed ID: 34783255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
    Davids MS; Kim HT; Nicotra A; Savell A; Francoeur K; Hellman JM; Bazemore J; Miskin HP; Sportelli P; Stampleman L; Maegawa R; Rueter J; Boruchov AM; Arnason JE; Jacobson CA; Jacobsen ED; Fisher DC; Brown JR;
    Lancet Haematol; 2019 Jan; 6(1):e38-e47. PubMed ID: 30558987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR).
    Špaček M; Smolej L; Šimkovič M; Nekvindová L; Křístková Z; Brychtová Y; Panovská A; Mašlejová S; Bezděková L; Écsiová D; Vodárek P; Zuchnická J; Mihályová J; Urbanová R; Turcsányi P; Lysák D; Novák J; Brejcha M; Líkařová T; Vodička P; Baranová J; Trněný M; Doubek M;
    Br J Haematol; 2023 Jul; 202(1):40-47. PubMed ID: 36971061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
    Sharman JP; Brander DM; Mato AR; Ghosh N; Schuster SJ; Kambhampati S; Burke JM; Lansigan F; Schreeder MT; Lunin SD; Zweibach A; Shtivelband M; Travis PM; Chandler JC; Kolibaba KS; Sportelli P; Miskin HP; Weiss MS; Flinn IW
    Lancet Haematol; 2021 Apr; 8(4):e254-e266. PubMed ID: 33631112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.
    Jain P; Thompson PA; Keating M; Estrov Z; Ferrajoli A; Jain N; Kantarjian H; Burger JA; O'Brien S; Wierda WG
    Cancer; 2017 Jun; 123(12):2268-2273. PubMed ID: 28171709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ibrutinib dose modifications in the management of CLL.
    Hardy-Abeloos C; Pinotti R; Gabrilove J
    J Hematol Oncol; 2020 Jun; 13(1):66. PubMed ID: 32503582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: a real-world analysis.
    Nunes RAB; Avezum Á; de Oliveira Marques M; Baiocchi OCCG; Bachour P
    Ann Hematol; 2024 Nov; 103(11):4613-4620. PubMed ID: 39153144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective observational study of ibrutinib in chronic lymphocytic leukaemia in a real-life setting in France using the national claims database (OSIRIS).
    Choquet S; Marchal C; Deygas F; Deslandes M; Macher N; de Pouvourville G; Levy V
    Ann Hematol; 2024 Aug; 103(8):2969-2981. PubMed ID: 38965145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
    O'Brien S; Jones JA; Coutre SE; Mato AR; Hillmen P; Tam C; Österborg A; Siddiqi T; Thirman MJ; Furman RR; Ilhan O; Keating MJ; Call TG; Brown JR; Stevens-Brogan M; Li Y; Clow F; James DF; Chu AD; Hallek M; Stilgenbauer S
    Lancet Oncol; 2016 Oct; 17(10):1409-1418. PubMed ID: 27637985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ibrutinib discontinuation in patients with relapsed or refractory chronic lymphocytic leukemia treated in a compassionate use program: A report from the Polish Adult Leukemia Study Group (PALG).
    Iskierka-Jażdżewska E; Puła B; Szeremet A; Hus M; Gołos A; Hołojda J; Piszczek W; Steckiewicz P; Wojciechowska M; Zaucha JM; Warzocha K; Jamroziak K
    Adv Clin Exp Med; 2019 Aug; 28(8):1051-1057. PubMed ID: 31199879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib.
    Jacobs R; Lu X; Emond B; Morrison L; Kinkead F; Lefebvre P; Lafeuille MH; Khan W; Wu LH; Qureshi ZP; Levy MY
    Future Oncol; 2024 Jan; 20(1):39-53. PubMed ID: 37476983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A real-world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first-line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United States.
    Mato A; Tang B; Azmi S; Yang K; Han Y; Zhang X; Roeker L; Wallis N; Stern JC; Hedrick E; Huang J; Sharman JP
    EJHaem; 2023 Feb; 4(1):135-144. PubMed ID: 36819172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.
    Kater AP; Levin MD; Dubois J; Kersting S; Enggaard L; Veldhuis GJ; Mous R; Mellink CHM; van der Kevie-Kersemaekers AF; Dobber JA; Poulsen CB; Frederiksen H; Janssens A; Schjødt I; Dompeling EC; Ranti J; Brieghel C; Mattsson M; Bellido M; Tran HTT; Nasserinejad K; Niemann CU
    Lancet Oncol; 2022 Jun; 23(6):818-828. PubMed ID: 35654052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study.
    Mauro FR; Scalzulli PR; Scarfò L; Minoia C; Murru R; Sportoletti P; Frigeri F; Albano F; Di Renzo N; Sanna A; Laurenti L; Massaia M; Cassin R; Coscia M; Patti C; Pennese E; Tafuri A; Chiarenza A; Galieni P; Perbellini O; Selleri C; Califano C; Ferrara F; Cuneo A; Murineddu M; Palumbo G; Scortechini I; Tedeschi A; Trentin L; Varettoni M; Pane F; Liberati AM; Merli F; Morello L; Musuraca G; Tani M; Ibatici A; Regazzoni G; Di Candia M; Palma M; Arienti D; Molica S
    Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia.
    Roeker LE; DerSarkissian M; Ryan K; Chen Y; Duh MS; Wahlstrom SK; Hakre S; Yu L; Guo H; Mato AR
    Blood Adv; 2023 Aug; 7(16):4291-4301. PubMed ID: 37163361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial.
    Hillmen P; Pitchford A; Bloor A; Broom A; Young M; Kennedy B; Walewska R; Furtado M; Preston G; Neilson JR; Pemberton N; Sidra G; Morley N; Cwynarski K; Schuh A; Forconi F; Elmusharaf N; Paneesha S; Fox CP; Howard DR; Hockaday A; Brown JM; Cairns DA; Jackson S; Greatorex N; Webster N; Shingles J; Dalal S; Patten PEM; Allsup D; Rawstron A; Munir T
    Lancet Oncol; 2023 May; 24(5):535-552. PubMed ID: 37142374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world experience of ibrutinib therapy in relapsed chronic lymphocytic leukemia: results of a single-center retrospective analysis.
    Nuttall E; Tung J; Trounce E; Johnston R; Chevassut T
    J Blood Med; 2019; 10():199-208. PubMed ID: 31372077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.